These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 29948178)

  • 41. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
    Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.
    Futamura Y; Asami T; Nonobe N; Kachi S; Ito Y; Sato Y; Hayakawa M; Terasaki H
    Jpn J Ophthalmol; 2015 Nov; 59(6):378-88. PubMed ID: 26265249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.
    Xia F; Lyu J; Peng J; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):2837-2846. PubMed ID: 35438363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
    Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
    J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
    Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
    BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
    Aldebasi T; Guma MA; Bashir R; Al Saif S; Altwaijri WA; Al Bekairy AM
    Med Princ Pract; 2019; 28(6):526-532. PubMed ID: 30995663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
    Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
    Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
    Sato T; Kusaka S; Shimojo H; Fujikado T
    Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.
    Wu L; Li M; Wang L; Yan H; Zhou Z; Fan J; Zhou Y; Gou K; Guo C; Wang Y; Zhang Z
    Sci Rep; 2023 Nov; 13(1):19946. PubMed ID: 37968276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab.
    Alyamaç Sukgen E; Çömez A; Koçluk Y; Cevher S
    Ophthalmologica; 2016; 236(3):139-147. PubMed ID: 27682852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
    Marlow N; Stahl A; Lepore D; Fielder A; Reynolds JD; Zhu Q; Weisberger A; Stiehl DP; Fleck B;
    Lancet Child Adolesc Health; 2021 Oct; 5(10):698-707. PubMed ID: 34391532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histopathologic Characterization of the Expression of Vascular Endothelial Growth Factor in a Case of Retinopathy of Prematurity Treated With Ranibizumab.
    Fernandez MP; Berrocal AM; Goff TC; Ghassibi MP; Harper CA; Chou E; Michael SK; Hellman J; Dubovy SR
    Am J Ophthalmol; 2017 Apr; 176():134-140. PubMed ID: 27993591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy.
    Shchuko AG; Zlobin IV; Iureva TN; Ostanin AA; Chernykh ER; Mikhalevich IM
    Indian J Ophthalmol; 2015 Dec; 63(12):905-11. PubMed ID: 26862095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry.
    Pfeil JM; Barth T; Lagrèze WA; Lorenz B; Hufendiek K; Liegl R; Breuss H; Bemme S; Aisenbrey S; Glitz B; Süsskind D; Gabel-Pfisterer A; Skevas C; Krohne TU; Kakkassery V; Bründer MC; Engelmann K; Guthoff R; Walter P; Choritz L; Stahl A;
    Ophthalmol Retina; 2024 Jun; 8(6):579-589. PubMed ID: 38104929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.